MannKind Corporation misses by $0.02

MannKind Corporation  (MNKD): Q4 EPS of -$0.16 misses by $0.02.

From other sites
Comments (7)
  • Keith_69
    , contributor
    Comments (177) | Send Message
    This is irrelevant to mnkd investors. The only news that matters to them is:


    1) partner
    2) FDA approval.
    18 Feb 2014, 09:55 AM Reply Like
  • patriot_invstr
    , contributor
    Comments (38) | Send Message
    @ Keith: Agreed, and not necessarily in that order.
    18 Feb 2014, 12:44 PM Reply Like
  • 3D Investing
    , contributor
    Comments (1552) | Send Message
    Chances are, Afrezza will be approved. The only chance it won't seems to be corruption. The FDA have demonstrated there's no shortage of corruption. However, I am sure the SEC is watching this time and so are tens of thousands of diabetic patients who've read about it or were on the trials. Doctors are waiting for it as well.


    If the FDA finds another crazy reason to reject it again, I'm sure there will be hell to pay. Right now, I'm more interested in knowing who will be the partner as that means potential market/marketing and rate of delivery.
    18 Feb 2014, 12:50 PM Reply Like
  • pilot fish
    , contributor
    Comments (147) | Send Message
    Cash on hand is the real issue and seems to have gone up from I expected. Hopefully the ECC will shed more light
    18 Feb 2014, 04:14 PM Reply Like
  • JRudin
    , contributor
    Comment (1) | Send Message
    I'm having trouble understanding why people think there will be such a demand for inhaler delivered insulin, at least for Type 1's. The speed at which the Afrezza works (and more importantly for diabetics) STOPS working, is impressive. However most type 1 diabetics are now on pens (which are more discrete than inhalers) or pumps (which constantly give a steady dose of insulin to simulate the pancreas. Using an inhaler for a bolus means probably taking lantus or NPH for a basal.
    18 Feb 2014, 08:43 PM Reply Like
  • jumbyj
    , contributor
    Comments (3) | Send Message
    The real market for inhaled insulin are the type 2s who are not well controlled and have refused to take insulin per injection. They are very willing to use an inhaler even coming in and asking about it.
    18 Feb 2014, 08:56 PM Reply Like
  • MrMcchumba
    , contributor
    Comments (17) | Send Message
    Correct! Speaking as one (1) of the 300 MILLION or so type 2's that should be taking a mealtime insulin, but who just doesn't want to start using needles, I am looking forward to the launch of Afrezza. Huge potential ROI here. Interesting note - a recent post by a SA member was an analysis of the oral insulin pill in development. The pill requires a high insulin dose and most of the insulin is lost in the digestion process. Insulin cost alone for the pill is at $100. per day for the average diabetic. No insurance company is going to pay that. This only increases Afrezza's viability.
    19 Feb 2014, 11:46 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs